Hormonal
Long-term treatment with semaglutide 2.4 mg (up to 68 weeks) produces significant weight loss (mean 14.5-14.8%) and improves cardiometabolic biomarkers (blood pressure, HbA1c, LDL, triglycerides) in real-world patients with obesity or overweight.
If you have obesity or overweight with a related health condition, semaglutide 2.4 mg taken once weekly can lead to significant weight loss (around 15% of body weight) and improvements in blood pressure, blood sugar, and cholesterol over a year. This is based on real-world data from thousands of patients, suggesting it works effectively outside of strict clinical trial settings. You must be willing to stay on the medication for at least a year to see these full benefits.
In this retrospective cohort study, the real-world effectiveness of semaglutide 2.4 mg was demonstrated by reductions in weight and BMI along with improvements in BP, HbA1c, and lipid panel among patients with obesity or overweight.
Why this rating
The study is a retrospective, noninterventional cohort study using real-world claims data, which is lower in hierarchy than randomized controlled trials but higher than case reports.
Source
Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months)
Aleksandrina Ruseva et al. · Postgraduate Medicine · 2025
DOI 10.1080/00325481.2025.2482274
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →